DEXCOM INC (DXCM) Fundamental Analysis & Valuation

NASDAQ:DXCM • US2521311074

Current stock price

63.84 USD
-1.84 (-2.8%)
Last:

This DXCM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. DXCM Profitability Analysis

1.1 Basic Checks

  • DXCM had positive earnings in the past year.
  • DXCM had a positive operating cash flow in the past year.
  • In the past 5 years DXCM has always been profitable.
  • Each year in the past 5 years DXCM had a positive operating cash flow.
DXCM Yearly Net Income VS EBIT VS OCF VS FCFDXCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

1.2 Ratios

  • DXCM has a better Return On Assets (13.19%) than 94.15% of its industry peers.
  • DXCM's Return On Equity of 30.46% is amongst the best of the industry. DXCM outperforms 97.34% of its industry peers.
  • DXCM has a Return On Invested Capital of 18.92%. This is amongst the best in the industry. DXCM outperforms 96.81% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for DXCM is significantly above the industry average of 9.40%.
  • The last Return On Invested Capital (18.92%) for DXCM is above the 3 year average (14.59%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.19%
ROE 30.46%
ROIC 18.92%
ROA(3y)10.24%
ROA(5y)8.29%
ROE(3y)28.01%
ROE(5y)22.13%
ROIC(3y)14.59%
ROIC(5y)11.66%
DXCM Yearly ROA, ROE, ROICDXCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 -20 30

1.3 Margins

  • DXCM's Profit Margin of 17.94% is amongst the best of the industry. DXCM outperforms 93.62% of its industry peers.
  • DXCM's Profit Margin has declined in the last couple of years.
  • DXCM has a Operating Margin of 21.55%. This is amongst the best in the industry. DXCM outperforms 93.62% of its industry peers.
  • DXCM's Operating Margin has improved in the last couple of years.
  • DXCM has a better Gross Margin (62.09%) than 65.43% of its industry peers.
  • In the last couple of years the Gross Margin of DXCM has declined.
Industry RankSector Rank
OM 21.55%
PM (TTM) 17.94%
GM 62.09%
OM growth 3Y15.68%
OM growth 5Y5.09%
PM growth 3Y15.23%
PM growth 5Y-8.86%
GM growth 3Y-1.61%
GM growth 5Y-1.72%
DXCM Yearly Profit, Operating, Gross MarginsDXCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

8

2. DXCM Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DXCM is creating value.
  • DXCM has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DXCM remains at a similar level compared to 5 years ago.
  • DXCM has a better debt/assets ratio than last year.
DXCM Yearly Shares OutstandingDXCM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
DXCM Yearly Total Debt VS Total AssetsDXCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • DXCM has an Altman-Z score of 6.37. This indicates that DXCM is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 6.37, DXCM belongs to the best of the industry, outperforming 81.38% of the companies in the same industry.
  • DXCM has a debt to FCF ratio of 1.20. This is a very positive value and a sign of high solvency as it would only need 1.20 years to pay back of all of its debts.
  • The Debt to FCF ratio of DXCM (1.20) is better than 89.89% of its industry peers.
  • A Debt/Equity ratio of 0.47 indicates that DXCM is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.47, DXCM is in line with its industry, outperforming 43.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1.2
Altman-Z 6.37
ROIC/WACC2.27
WACC8.34%
DXCM Yearly LT Debt VS Equity VS FCFDXCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • A Current Ratio of 1.88 indicates that DXCM should not have too much problems paying its short term obligations.
  • The Current ratio of DXCM (1.88) is worse than 65.96% of its industry peers.
  • DXCM has a Quick Ratio of 1.59. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
  • DXCM's Quick ratio of 1.59 is in line compared to the rest of the industry. DXCM outperforms 42.55% of its industry peers.
  • DXCM does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.59
DXCM Yearly Current Assets VS Current LiabilitesDXCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

7

3. DXCM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.73% over the past year.
  • Measured over the past years, DXCM shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.29% on average per year.
  • Looking at the last year, DXCM shows a quite strong growth in Revenue. The Revenue has grown by 15.60% in the last year.
  • DXCM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.33% yearly.
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
Revenue 1Y (TTM)15.6%
Revenue growth 3Y17.01%
Revenue growth 5Y19.33%
Sales Q2Q%13.12%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.71% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 11.94% on average over the next years. This is quite good.
EPS Next Y36.69%
EPS Next 2Y27.75%
EPS Next 3Y24.99%
EPS Next 5Y21.71%
Revenue Next Year12.62%
Revenue Next 2Y12.47%
Revenue Next 3Y12.38%
Revenue Next 5Y11.94%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DXCM Yearly Revenue VS EstimatesDXCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
DXCM Yearly EPS VS EstimatesDXCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4

6

4. DXCM Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 34.32, the valuation of DXCM can be described as expensive.
  • DXCM's Price/Earnings ratio is a bit cheaper when compared to the industry. DXCM is cheaper than 71.28% of the companies in the same industry.
  • DXCM is valuated rather expensively when we compare the Price/Earnings ratio to 26.91, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 25.11 indicates a quite expensive valuation of DXCM.
  • Based on the Price/Forward Earnings ratio, DXCM is valued a bit cheaper than the industry average as 74.47% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of DXCM to the average of the S&P500 Index (23.68), we can say DXCM is valued inline with the index average.
Industry RankSector Rank
PE 34.32
Fwd PE 25.11
DXCM Price Earnings VS Forward Price EarningsDXCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 75.00% of the companies in the same industry are more expensive than DXCM, based on the Enterprise Value to EBITDA ratio.
  • 84.57% of the companies in the same industry are more expensive than DXCM, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 22.81
EV/EBITDA 18.7
DXCM Per share dataDXCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • DXCM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of DXCM may justify a higher PE ratio.
  • DXCM's earnings are expected to grow with 24.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.94
PEG (5Y)1.78
EPS Next 2Y27.75%
EPS Next 3Y24.99%

0

5. DXCM Dividend Analysis

5.1 Amount

  • DXCM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

DXCM Fundamentals: All Metrics, Ratios and Statistics

DEXCOM INC

NASDAQ:DXCM (4/10/2026, 3:14:02 PM)

63.84

-1.84 (-2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-30
Inst Owners100.29%
Inst Owner Change0.01%
Ins Owners0.2%
Ins Owner Change9.44%
Market Cap24.57B
Revenue(TTM)4.66B
Net Income(TTM)836.30M
Analysts84.86
Price Target88.6 (38.78%)
Short Float %4.26%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.4%
Min EPS beat(2)-32.12%
Max EPS beat(2)5.32%
EPS beat(4)2
Avg EPS beat(4)-6.03%
Min EPS beat(4)-32.12%
Max EPS beat(4)6.77%
EPS beat(8)5
Avg EPS beat(8)-1.11%
EPS beat(12)9
Avg EPS beat(12)9.15%
EPS beat(16)11
Avg EPS beat(16)5.86%
Revenue beat(2)1
Avg Revenue beat(2)-0.14%
Min Revenue beat(2)-0.9%
Max Revenue beat(2)0.61%
Revenue beat(4)2
Avg Revenue beat(4)0.1%
Min Revenue beat(4)-0.9%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-1.02%
Revenue beat(12)5
Avg Revenue beat(12)-0.35%
Revenue beat(16)6
Avg Revenue beat(16)-0.53%
PT rev (1m)0.3%
PT rev (3m)0.07%
EPS NQ rev (1m)0.17%
EPS NQ rev (3m)-0.14%
EPS NY rev (1m)0%
EPS NY rev (3m)0.83%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-0.66%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.04%
Valuation
Industry RankSector Rank
PE 34.32
Fwd PE 25.11
P/S 5.27
P/FCF 22.81
P/OCF 17.05
P/B 8.95
P/tB 9.27
EV/EBITDA 18.7
EPS(TTM)1.86
EY2.91%
EPS(NY)2.54
Fwd EY3.98%
FCF(TTM)2.8
FCFY4.38%
OCF(TTM)3.74
OCFY5.86%
SpS12.11
BVpS7.14
TBVpS6.89
PEG (NY)0.94
PEG (5Y)1.78
Graham Number17.28
Profitability
Industry RankSector Rank
ROA 13.19%
ROE 30.46%
ROCE 23.93%
ROIC 18.92%
ROICexc 36.12%
ROICexgc 37.75%
OM 21.55%
PM (TTM) 17.94%
GM 62.09%
FCFM 23.11%
ROA(3y)10.24%
ROA(5y)8.29%
ROE(3y)28.01%
ROE(5y)22.13%
ROIC(3y)14.59%
ROIC(5y)11.66%
ROICexc(3y)37.89%
ROICexc(5y)31.72%
ROICexgc(3y)41.79%
ROICexgc(5y)35.48%
ROCE(3y)18.46%
ROCE(5y)14.75%
ROICexgc growth 3Y1.89%
ROICexgc growth 5Y6.96%
ROICexc growth 3Y7.33%
ROICexc growth 5Y6.44%
OM growth 3Y15.68%
OM growth 5Y5.09%
PM growth 3Y15.23%
PM growth 5Y-8.86%
GM growth 3Y-1.61%
GM growth 5Y-1.72%
F-Score8
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1.2
Debt/EBITDA 1.03
Cap/Depr 144.36%
Cap/Sales 7.8%
Interest Coverage 88.12
Cash Conversion 114.67%
Profit Quality 128.81%
Current Ratio 1.88
Quick Ratio 1.59
Altman-Z 6.37
F-Score8
WACC8.34%
ROIC/WACC2.27
Cap/Depr(3y)145.46%
Cap/Depr(5y)210.39%
Cap/Sales(3y)7.74%
Cap/Sales(5y)10.33%
Profit Quality(3y)110.93%
Profit Quality(5y)89.33%
High Growth Momentum
Growth
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
EPS Next Y36.69%
EPS Next 2Y27.75%
EPS Next 3Y24.99%
EPS Next 5Y21.71%
Revenue 1Y (TTM)15.6%
Revenue growth 3Y17.01%
Revenue growth 5Y19.33%
Sales Q2Q%13.12%
Revenue Next Year12.62%
Revenue Next 2Y12.47%
Revenue Next 3Y12.38%
Revenue Next 5Y11.94%
EBIT growth 1Y53.73%
EBIT growth 3Y35.36%
EBIT growth 5Y25.41%
EBIT Next Year68.67%
EBIT Next 3Y32.44%
EBIT Next 5Y25.77%
FCF growth 1Y70.79%
FCF growth 3Y52.34%
FCF growth 5Y31.25%
OCF growth 1Y45.6%
OCF growth 3Y29.1%
OCF growth 5Y24.81%

DEXCOM INC / DXCM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DEXCOM INC?

ChartMill assigns a fundamental rating of 7 / 10 to DXCM.


What is the valuation status of DEXCOM INC (DXCM) stock?

ChartMill assigns a valuation rating of 6 / 10 to DEXCOM INC (DXCM). This can be considered as Fairly Valued.


What is the profitability of DXCM stock?

DEXCOM INC (DXCM) has a profitability rating of 8 / 10.


How financially healthy is DEXCOM INC?

The financial health rating of DEXCOM INC (DXCM) is 8 / 10.